Third Party Mesenchymal Stromal Cell Infusion in Kidney Transplant Recipient: 6-Month Safety Interim Analysis
1Nephrology, University Hospital of Liege, Liege, Belgium
2Hematology, University Hospital of Liege, Liege, Belgium
3Abdominal Surgery, University Hospital of Liege, Liege, Belgium.
Meeting: 2015 American Transplant Congress
Abstract number: B55
Keywords: Immunosuppression, Kidney transplantation, Stem cells
Session Information
Session Name: Poster Session B: Cell Transplantation and Cell Therapies
Session Type: Poster Session
Date: Sunday, May 3, 2015
Session Time: 5:30pm-6:30pm
Presentation Time: 5:30pm-6:30pm
Location: Exhibit Hall E
Back-ground
Mesenchymal stromal cell (MSC) have immunomodulating properties and could be used as immunosuppressive agents.
We report the 6-month safety results for the 5 first patients treated with MSC after kidney transplantation (KTx). Here, we address 3 specific safety issues:
– Immunization against MSC
– Engraftment syndrome defined as acute graft dysfunction not related to rejection
– Over-immunosuppression.
Patients and method
MSC production was carried out locally. MSC were not matched with kidney recipients' HLA. Included patients were non-immunized, first transplant recipient from deceased donors. MSC (1.5 – 3.0 x 106/kg) infusion was planned 3 to 5 days post KTx. Patients with cardiovascular instability post KTx were excluded. All patients were treated with Basiliximab induction, Tacrolimus, Mycophenolate Mofetil and Steroid. We prospectively screened for anti-HLA antibodies at month 1, 3 and 6. Informed consent was obtained from all participants. The local ethical committee approved the protocol.
Results
Collectively there were 23/50 and 29/50 HLA mismatches (MM) with kidney and MSC donor respectively, out of which 5 were shared MM.
| Recipient | Age at Tx (years) | 63 ± 6 |
|---|---|---|
| Gender (M/F) | 4/1 | |
| BMI (kg/m2) | 27 ± 3 | |
| Dialysis vintage (days) | 373 ± 564 | |
| Kidney donor | Age (years) | 51 ± 18 |
| Gender (M/F) | 3/2 | |
| BMI (kg/m2) | 26 ± 5 | |
| DBD/DCD | 4/1 | |
| Transplantation | CIT (min) | 737 ± 219 |
| WIT (min) | 46 ± 16 | |
| HLA mismatches (n) | ||
| A (0/1/2) | 0/5/0 | |
| B (0/1/2) | 1/4/0 | |
| Cw (0/1/2) | 1/3/1 | |
| DR (0/1/2) | 1/4/0 | |
| DQ (0/1/2) | ||
| MSC donor | HLA mismatches (n) | |
| A (0/1/2) | 1/2/2 | |
| B (0/1/2) | 1/3/1 | |
| Cw (0/1/2) | 0/4/1 | |
| DR (0/1/2) | 1/3/1 | |
| DQ (0/1/2) | 0/3/2 |
One patient developed de novo DSA, 2 patients anti-HLA antibodies against shared kidney/MSC MM and 1 patient developed 2 specific antibodies against MSC (MSCSA) at month 6. All antibodies were anti HLA class I except for 1.
We did not observe any “engraftment” syndrome.
Three patients experienced non-severe opportunistic infections: 1 CMV reactivation and 2 polyoma-BK virus viremia.
Conclusion
We did not observe any strong safety signal. We did however observe some degree of immunization in 3 patients: 2 developed antibodies against shared kidney/MSC donor HLA MM and 1 MSCSA.
To cite this abstract in AMA style:
Weekers L, Erpicum P, Detry O, Lechanteur C, Baudoux E, Jouret F, Beguin Y. Third Party Mesenchymal Stromal Cell Infusion in Kidney Transplant Recipient: 6-Month Safety Interim Analysis [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/third-party-mesenchymal-stromal-cell-infusion-in-kidney-transplant-recipient-6-month-safety-interim-analysis/. Accessed May 15, 2025.« Back to 2015 American Transplant Congress